Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
04
05
2022
received:
28
02
2022
accepted:
05
05
2022
pubmed:
15
5
2022
medline:
16
11
2022
entrez:
14
5
2022
Statut:
ppublish
Résumé
A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series. We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18-79) years at presentation. Liver injury was diagnosed a median 15 (range: 3-65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3-4 liver injury than for grade 1-2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up. SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient.
Sections du résumé
BACKGROUND AND AIMS
A few case reports of autoimmune hepatitis-like liver injury have been reported after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We evaluated clinical features, treatment response and outcomes of liver injury following SARS-CoV-2 vaccination in a large case series.
APPROACH AND RESULTS
We collected data from cases in 18 countries. The type of liver injury was assessed with the R-value. The study population was categorized according to features of immune-mediated hepatitis (positive autoantibodies and elevated immunoglobulin G levels) and corticosteroid therapy for the liver injury. We identified 87 patients (63%, female), median age 48 (range: 18-79) years at presentation. Liver injury was diagnosed a median 15 (range: 3-65) days after vaccination. Fifty-one cases (59%) were attributed to the Pfizer-BioNTech (BNT162b2) vaccine, 20 (23%) cases to the Oxford-AstraZeneca (ChAdOX1 nCoV-19) vaccine and 16 (18%) cases to the Moderna (mRNA-1273) vaccine. The liver injury was predominantly hepatocellular (84%) and 57% of patients showed features of immune-mediated hepatitis. Corticosteroids were given to 46 (53%) patients, more often for grade 3-4 liver injury than for grade 1-2 liver injury (88.9% vs. 43.5%, p = 0.001) and more often for patients with than without immune-mediated hepatitis (71.1% vs. 38.2%, p = 0.003). All patients showed resolution of liver injury except for one man (1.1%) who developed liver failure and underwent liver transplantation. Steroid therapy was withdrawn during the observation period in 12 (26%) patients after complete biochemical resolution. None had a relapse during follow-up.
CONCLUSIONS
SARS-CoV-2 vaccination can be associated with liver injury. Corticosteroid therapy may be beneficial in those with immune-mediated features or severe hepatitis. Outcome was generally favorable, but vaccine-associated liver injury led to fulminant liver failure in one patient.
Identifiants
pubmed: 35567545
doi: 10.1002/hep.32572
pmc: PMC9348326
pii: 01515467-202212000-00005
doi:
Substances chimiques
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1576-1586Informations de copyright
© 2022 American Association for the Study of Liver Diseases.
Références
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.
Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera‐de la Tijera F, Aloman C, et al. Outcome of COVID‐19 in patients with autoimmune hepatitis: an international multicenter study. Hepatology. 2021;73:2099–109.
Khandker SS, Godman B, Jawad MI, Meghla BA, Tisha TA, Khondoker MU, et al. A systematic review on COVID‐19 vaccine strategies, their effectiveness, and issues. Vaccines (Basel). 2021;9:1387.
Teijaro JR, Farber DL. COVID‐19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195–7.
Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID‐19 vaccines: a systematic review and meta‐analysis. Front Immunol. 2021;12:714170. https://doi.org/10.3389/fimmu.2021.714170
doi: 10.3389/fimmu.2021.714170
Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New‐onset autoimmune phenomena post COVID‐19 vaccination. Immunology. 2021;165:386–401. https://doi.org/10.1111/imm.13443
doi: 10.1111/imm.13443
Bril F, Al Diffalha S, Dean M, Fettig DM. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID‐19) vaccine: causality or casualty? J Hepatol. 2021;75:222–4.
Shroff H, Satapathy SK, Crawford JM, Todd NJ, VanWagner LB. Liver injury following SARS‐CoV‐2 vaccination: a multicenter case series. J Hepatol. 2022;76:211–4.
Cao Z, Gui H, Sheng Z, Xin H, Xie Q. Letter to the editor: exacerbation of autoimmune hepatitis after COVID‐19 vaccination. Hepatology. 2022;75:757–9.
Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology. 2022. https://doi.org/10.1002/hep.32327
doi: 10.1002/hep.32327
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug‐induced liver injury. Clin Pharmacol Ther. 2011;89:806–15.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.
Garrido I, Lopes S, Simões MS, Liberal R, Lopes J, Carneiro F, et al. Autoimmune hepatitis after COVID‐19 vaccine ‐ more than a coincidence. J Autoimmun. 2021;125:102741.
Avci E, Abasiyanik F. Autoimmune hepatitis after SARS‐CoV‐2 vaccine: new‐onset or flare‐up? J Autoimmun. 2021;125:102745.
Londoño MC, Gratacós‐Ginès J, Sáez‐Peñataro J. Another case of autoimmune hepatitis after SARS‐CoV‐2 vaccination – still casualty? J Hepatol. 2021;75:1248–9.
Clayton‐Chubb D, Schneider D, Freeman E, Kemp W, Roberts SK. Autoimmune hepatitis developing after the ChAdOx1 nCoV‐19 (Oxford‐AstraZeneca) vaccine. J Hepatol. 2021;75:1249–50.
Tan CK, Wong YJ, Wang LM, Ang TL, Kumar R. Autoimmune hepatitis following COVID‐19 vaccination: true causality or mere association? J Hepatol. 2021;75:1250–2.
Palla P, Vergadis C, Sakellariou S, Androutsakos T. Letter to the editor: autoimmune hepatitis after COVID‐19 vaccination: a rare adverse effect? Hepatology. 2022;75:489–90.
Ghielmetti M, Schaufelberger HD, Mieli‐Vergani G, Cerny A, Dayer E, Vergani D, et al. Acute autoimmune‐like hepatitis with atypical anti‐mitochondrial antibody after mRNA COVID‐19 vaccination: a novel clinical entity? J Autoimmun. 2021;123:102706.
Vojdani A, Kharrazian D. Potential antigenic cross‐reactivity between SARS‐CoV‐2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 2020;217:108480.
Weiler‐Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol. 2011;55:747–9.
Efe C, Harputluoğlu M, Soylu NK, Yilmaz S. Letter to the editor: Liver transplantation following severe acute respiratory syndrome‐coronavirus‐2 vaccination‐induced liver failure. Hepatology. 2022;75:1669–71.
Suzuki Y, Kakisaka K, Takikawa Y. Letter to the editor: autoimmune hepatitis after COVID‐19 vaccination: need for population‐based epidemiological study. Hepatology. 2022;75:759–60.
Björnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S. Drug‐induced autoimmune hepatitis: response to corticosteroids and lack of relapse after cessation of steroids. Clin Gastroenterol Hepatol. 2017;15:1635–6.
Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug‐induced liver injury. Hepatology. 2011;54:931–9.
Efe C, Ozaslan E, Wahlin S, Purnak T, Muratori L, Quarneti C, et al. Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study. Liver Int. 2013;33:190–6.
Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, et al. Drug‐induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–8.
Andrade RJ, Chalasani N, Bjornsson ES, Suzuki A, Kullak‐Ublick GA, Watkins PB, et al. Drug‐induced liver injury. Nat Rev Dis Primers. 2019;5:58.
Efe C, Heurgué‐Berlot A, Ozaslan E, Purnak T, Thiéfin G, Simsek H, et al. Late autoimmune hepatitis after hepatitis C therapy. Eur J Gastroenterol Hepatol. 2013;25:1308–11.
Zoubek ME, Lucena MI, Andrade RJ, Stephens C. Systematic review: ibuprofen‐induced liver injury. Aliment Pharmacol Ther. 2020;51:603–11.
Zin Tun GS, Gleeson D, Al‐Joudeh A, Dube A. Immune‐mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed. J Hepatol. 2022;76:747–9.
Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV‐19 and mRNA prime‐boost vaccination against symptomatic Covid‐19 infection in Sweden: a nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249.
Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab‐induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol. 2022;76:86–92.
Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: insights from an analysis of 500 cases. Clin Immunol. 2019;203:1–8.
Van Gemeren MAJ, van Wijngaarden P, Doukas M, de Man RA. Vaccine‐related autoimmune hepatitis: the same disease as idiopathic autoimmune hepatitis? Two clinical reports and review. Scand J Gastroenterol. 2017;52:18–22.